Position | PhosphoPeptide | Catalytic kinase | Source |
---|
S238 | SEEEQsSSSVK | Viral_P18; Alpha-2-MRAP_C | PhosphoSitePlus |
S306 | NGED | | HPRD; phosphoELM |
S108 | EMYGSsFDLDY | | HPRD |
S138 | YDRMYsYPARV | | PhosphoSitePlus; HPRD; phosphoELM; RegPhos |
S286 | EDDRDsANGED | | HPRD |
S166 | VSGNTsRRGKS | | PhosphoSitePlus |
S240 | NVKMEsEGGAD | | HPRD |
S260 | GGADDsAEEGD | CSNK2A2 | HPRD |
S239 | EEEQSsSSVKK | | HPRD; phosphoELM; RegPhos |
S299 | EDDRDsANGED | CK1_alpha | phosphoELM |
S121 | PLLSSsFDLDY | | PhosphoSitePlus; phosphoELM |
S31 | LVVKKsDVEAI | RRM_1 | PhosphoSitePlus |
S162 | KSGFNsKSGQR | | HPRD |
S260 | GGADDsAEEGD | CSNK2A1 | HPRD |
S253 | NVKMEsEGGAD | CK1_alpha | phosphoELM |
Y57 | FAFVQyVNERN | RRM_1 | PhosphoSitePlus |
S253 | NVKMEsEGGAD | CSNK1A1 | HPRD |
T234 | VKKDEtNVKME | | HPRD |
S260 | GGADDsAEEGD | | HPRD; phosphoELM; RegPhos |
S119 | PSPLLsSSFDL | | PhosphoSitePlus; HPRD |
S183 | GQRGSsKSGKL | | HPRD |
S306 | NGEDDs_____ | | PhosphoSitePlus |
S240 | EEQSSsSVKKD | | HPRD; phosphoELM; RegPhos |
S175 | KSGFNsKSGQR | | HPRD |
T247 | VKKDEtNVKME | | HPRD |
S115 | EHPSPsPLLSS | | PhosphoSitePlus; HPRD; phosphoELM |
T109 | MYGSVtEHPSP | | PhosphoSitePlus; HPRD; phosphoELM |
S239 | EEEQSsSSVKK | Viral_P18; Alpha-2-MRAP_C | PhosphoSitePlus |
S247 | GGADDsAEEGD | CSNK2A2 | HPRD |
S107 | AEMYGsVTEHP | | HPRD |
Y105 | SAAEMyGSSFD | | HPRD |
S260 | GGADDsAEEGD | CK2a1-rs | RegPhos |
S238 | SEEEQsSSSVK | | HPRD; phosphoELM; RegPhos |
S233 | MKNDKsEEEQS | Viral_P18; Alpha-2-MRAP_C | PhosphoSitePlus |
Y139 | DRMYSyPARVP | | PhosphoSitePlus |
S241 | EQSSSsVKKDE | | HPRD; phosphoELM; RegPhos |
S225 | SEEEQsSSSVK | | HPRD |
S253 | NVKMEsEGGAD | CK1a | RegPhos |
S299 | EDDRDsANGED | | HPRD; phosphoELM; RegPhos |
Y137 | YYDRMySYPAR | | PhosphoSitePlus |
S247 | GGADDsAEEGD | | HPRD |
S253 | NVKMEsEGGAD | | HPRD; phosphoELM; RegPhos |
S240 | EEQSSsSVKKD | CK1a | RegPhos |
S149 | KRQRVsGNTSR | | HPRD |
S38 | VEAIFsKYGKI | RRM_1 | PhosphoSitePlus |
S293 | NGED | | HPRD |
S260 | GGADDsAEEGD | CK2a1 | RegPhos |
S260 | GGADDsAEEGD | CK2a2 | RegPhos |
S260 | GGADDsAEEGD | CK1a(CK1 alpha | RegPhos |
S125 | YDRMYsYPARV | | HPRD |
S156 | RAVVPsKRQRV | | PhosphoSitePlus; HPRD |
S299 | EDDRDsANGED | RP-C_C | PhosphoSitePlus |
S228 | EQSSSsVKKDE | | HPRD |
S209 | KQKVDsLLENL | Viral_P18; Alpha-2-MRAP_C | PhosphoSitePlus |
S226 | EEEQSsSSVKK | | HPRD |
S299 | EDDRDsANGED | CK1a(CK1 alpha | RegPhos |
S162 | KRQRVsGNTSR | | PhosphoSitePlus; HPRD; phosphoELM; RegPhos |
S240 | NVKMEsEGGAD | CSNK1A1 | HPRD |
Y105 | SAAEMyGSVTE | | phosphoELM |
Y132 | DFQRDyYDRMY | | PhosphoSitePlus |
Y126 | SFDLDyDFQRD | | PhosphoSitePlus |
S241 | EQSSSsVKKDE | Alpha-2-MRAP_C; DUF2422; | PhosphoSitePlus |
S253 | NVKMEsEGGAD | CK1a(CK1 alpha | RegPhos |
S143 | RAVVPsKRQRV | | HPRD |
S260 | GGADDsAEEGD | CK2_group | phosphoELM; RegPhos |
T165 | RVSGNtSRRGK | | PhosphoSitePlus |
S113 | VTEHPsPSPLL | | PhosphoSitePlus; HPRD; phosphoELM |
S170 | GQRGSsKSGKL | | HPRD |
S227 | EEQSSsSVKKD | | HPRD |
S240 | EEQSSsSVKKD | Viral_P18; Alpha-2-MRAP_C | PhosphoSitePlus |
S260 | GGADDsAEEGD | Alpha-2-MRAP_C; DUF2422; | PhosphoSitePlus |
S220 | MKNDKsEEEQS | | HPRD |
S107 | AEMYGsSFDLD | | HPRD |
S120 | SPLLSsSFDLD | | PhosphoSitePlus; phosphoELM |
S100 | AGVKRsAAEMY | | HPRD; phosphoELM |
S306 | NGEDDs | | RegPhos |
S247 | GGADDsAEEGD | CSNK2A1 | HPRD |
S253 | NVKMEsEGGAD | Alpha-2-MRAP_C; DUF2422; | PhosphoSitePlus |
S260 | GGADDsAEEGD | CK1_alpha | phosphoELM |
S233 | MKNDKsEEEQS | | HPRD; phosphoELM; RegPhos |
Y133 | FQRDYyDRMYS | | PhosphoSitePlus |
|
Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
---|
ENSP00000319690 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Up | 5.5 | 18646787 |
ENSP00000319690 | Uterine Cancer | Normal vs. Cancer | tissue | Up | | 17902640 |
ENSP00000319690 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 2.3 | 17627933 |
ENSP00000319690 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) silenced) | cell line | Up | 2.2 | 17854218 |
ENSP00000319690 | Colorectal Cancer | Treatment (none vs transfected with HPV-16 E6 gene) | cell line | Down | | 15684709 |
ENSP00000319690 | Colorectal Cancer | Treatment (none vs transfected with HPV-16 E6 gene) | cell line | Down | | 15684709 |
ENSP00000319690 | Lung Cancer | Treatment(none vs 20 mg/mL GTE treatment) | cell line | Up | 2.1 | 19137550 |
ENSP00000319690 | Lung Cancer | Treatment(none vs 40 mg/mL GTE treatment) | cell line | Up | 1.3 | 19137550 |
ENSP00000319690 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.33 | 20804217 |
ENSP00000319690 | Oral Cancer | Normal vs. Cancer | tissue | Up | 3 | 19691830 |
ENSP00000319690 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | | 17655343 |
ENSP00000319690 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.08 | 17655343 |
ENSP00000319690 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Down | 0.11 | 17655343 |
ENSP00000319690 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | | 17655343 |
ENSP00000319690 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | | 17655343 |
|